TREMFYA® is now approved for pediatric patients living with moderate to severe plaque psoriasis, who are candidates for systemic therapy or phototherapy, and active psoriatic arthritis in children six ...

*The as observed analysis set included participants who entered the LTE, received ≥1 partial or complete study drug dose during the LTE, remained on treatment, and had data available at Week 96; ...

The decision is supported by the Phase 3 PROTOSTAR study, where guselkumab demonstrated higher levels of skin clearance vs. placebo at Week 16. 2 Almost one-third of Pso cases begin in childhood, and ...

TREMFYA® is the only IL-23 inhibitor to demonstrate superiority to ustekinumab in the overall population of patients with Crohn's disease, inclusive of those who are biologic-naïve and ...

The first and only dual-acting interleukin-23 inhibitor approved in active ulcerative colitis, TREMFYA® showed highly statistically significant rates of endoscopic remission at one year in the pivotal ...

Johnson & Johnson (J&J) Innovation Medicine has submitted a request to the US Food and Drug Administration (FDA) to approve a new way of starting treatment with its drug Tremfya (guselkumab) for ...

"Despite advancements in the treatment of pediatric plaque psoriasis and active psoriatic arthritis, there continues to be a significant gap in available therapies for these debilitating ...

Almost one-third of Pso cases begin in childhood, and the inflamed, scaly plaques caused by chronic disease may be itchy or painful and can be highly stressful for children, leading to a potential ...

Guselkumab has received approval for moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy.1 The decision is supported by the ...